Evidence map›Paper›PMID 42525778›Full record

ArticleScience advances2026

A comprehensive map of missense trafficking variants in rhodopsin and their response to pharmacologic correction.

Kannan V Manian, Connor H Ludwig, Yan Zhao, Nathan S Abell, Robert Warneford-Thomson, Henry Chan, Zachary O Casey, Xiaoping Yang, David E Root, Matthew L Albert and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Expanding the clinical and genetic spectrum ofExperimental biology and medicine (Maywood, N.J.) · 2026
    Article
  3. Review
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Kannan V ManianOcular Genomics Institute, Berman-Gund Laboratory for the Study of Retinal Degenerations, Mass Eye and Ear, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-1764-2424
Connor H LudwigOctant, Inc., Emeryville, CA, USA.ORCID 0000-0002-9159-7628
Yan ZhaoOcular Genomics Institute, Berman-Gund Laboratory for the Study of Retinal Degenerations, Mass Eye and Ear, Harvard Medical School, Boston, MA, USA.ORCID 0009-0007-4987-5325
Nathan S AbellOctant, Inc., Emeryville, CA, USA.ORCID 0000-0003-1098-5395
Robert Warneford-ThomsonOctant, Inc., Emeryville, CA, USA.ORCID 0000-0002-4521-0568
Henry ChanOctant, Inc., Emeryville, CA, USA.ORCID 0009-0008-5927-3587
Zachary O CaseyMolecular Biology Institute, University of California, Los Angeles, CA, USA.
Xiaoping YangGenetic Perturbation Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0002-6811-4915
David E RootGenetic Perturbation Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0001-5122-861X
Matthew L AlbertOctant, Inc., Emeryville, CA, USA.ORCID 0000-0001-7285-6973
Jason ComanderOcular Genomics Institute, Berman-Gund Laboratory for the Study of Retinal Degenerations, Mass Eye and Ear, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-4257-7145

Funding

P30 Core Grant for Vision ResearchP30EY014104 · NEI · MASSACHUSETTS EYE AND EAR INFIRMARY · PI Janey L Wiggs · 2002 to 2026
$15.1M
Improving the throughput of diagnosis and treatment of inherited diseases of the retinaR01EY031036 · NEI · MASSACHUSETTS EYE AND EAR INFIRMARY · PI COMANDER, JASON · 2020 to 2024
$2.1M
NEI NIH HHS P30 EY014104NEI NIH HHS R01 EY031036
6 · The paper itself

Abstract

Rhodopsin (

Indexed as

Mutation, MissenseRetinitis PigmentosaRhodopsinHumansProtein TransportRhodopsin

Identifiers

PMID42525778
PMCPMC13418928

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.